Jefferson Bridge Capital LLC Buys Shares of 52,798 Harrow, Inc. $HROW

Jefferson Bridge Capital LLC bought a new stake in Harrow, Inc. (NASDAQ:HROW) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 52,798 shares of the company’s stock, valued at approximately $2,587,000. Harrow makes up about 2.6% of Jefferson Bridge Capital LLC’s portfolio, making the stock its 14th largest holding. Jefferson Bridge Capital LLC owned approximately 0.14% of Harrow as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in shares of Harrow during the second quarter worth $48,000. State of Alaska Department of Revenue acquired a new stake in shares of Harrow during the third quarter worth $83,000. Tower Research Capital LLC TRC lifted its stake in shares of Harrow by 345.0% during the second quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock worth $103,000 after buying an additional 2,615 shares during the period. Larson Financial Group LLC lifted its stake in shares of Harrow by 848.2% during the third quarter. Larson Financial Group LLC now owns 2,162 shares of the company’s stock worth $104,000 after buying an additional 1,934 shares during the period. Finally, Strs Ohio acquired a new stake in shares of Harrow during the first quarter worth $149,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Stock Up 0.9%

HROW opened at $35.43 on Wednesday. Harrow, Inc. has a fifty-two week low of $20.85 and a fifty-two week high of $54.85. The company has a debt-to-equity ratio of 4.67, a quick ratio of 2.06 and a current ratio of 2.20. The company has a fifty day moving average of $41.75 and a two-hundred day moving average of $43.05. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -208.40 and a beta of 0.31.

Analysts Set New Price Targets

Several equities research analysts have recently commented on HROW shares. HC Wainwright reiterated a “buy” rating and set a $70.00 price objective on shares of Harrow in a research note on Thursday, March 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a research note on Thursday, January 22nd. BTIG Research reiterated a “buy” rating and set a $63.00 price objective on shares of Harrow in a research note on Wednesday, March 18th. Nomura downgraded shares of Harrow to a “neutral” rating in a research note on Wednesday, March 18th. Finally, William Blair reiterated an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $69.86.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.